A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis

Completed

• Conditions: Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Psoriasis

• Registration Number: NCT05796245
• Lead Sponsor: Pfizer

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-3-2
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

Inclusion criteria<br><br> 1. Have at least 90 days of look-back period<br><br> 2. Have diagnostic code of indicated diseases (rheumatoid arthritis, ulcerative<br> colitis, Crohn's disease, or psoriasis) in the 90-day look-back period. Patients<br> with >1 indication will be summarized as a separate group from each sub-cohort. An<br> inpatient or outpatient visit assigned a diagnosis code consistent with either<br> rheumatoid arthritis, ulcerative colitis, Crohn's disease, or psoriasis using ICD-10<br> coding.<br><br> 3. 15 years of age or older at the time of index date<br><br>Exclusion criteria<br><br> 1. Patients with pre-existing safety outcome event during the 90-day look-back period<br> will be excluded from the study cohort for that specific outcome event as this study<br> is observing incident cases.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence rate of Serious infections

Secondary Outcome Measures

Name	Time	Method
Incidence rate of tuberculosis;Incidence rate of serious blood disorder;Incidence rate of interstitial pneumonia;Incidence rate of malignancy